Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022
Cyanobacteria ascribed to the genus <i>Lyngbya</i> (Family Oscillatoriaceae) represent a potential therapeutic gold mine of chemically and biologically diverse natural products that exhibit a wide array of biological properties. Phylogenetic analyses have established the <i>Lyngbya...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1660-3397/20/12/768 |
| _version_ | 1797456577329889280 |
|---|---|
| author | Diaa T. A. Youssef Shatha J. Mufti Abeer A. Badiab Lamiaa A. Shaala |
| author_facet | Diaa T. A. Youssef Shatha J. Mufti Abeer A. Badiab Lamiaa A. Shaala |
| author_sort | Diaa T. A. Youssef |
| collection | DOAJ |
| description | Cyanobacteria ascribed to the genus <i>Lyngbya</i> (Family Oscillatoriaceae) represent a potential therapeutic gold mine of chemically and biologically diverse natural products that exhibit a wide array of biological properties. Phylogenetic analyses have established the <i>Lyngbya</i> ‘morpho-type’ as a highly polyphyletic group and have resulted in taxonomic revision and description of an additional six new cyanobacterial genera in the same family to date. Among the most prolific marine cyanobacterial producers of biologically active compounds are the species <i>Moorena producens</i> (previously <i>L. majuscula,</i> then <i>Moorea producens</i>)<i>, M. bouillonii</i> (previously <i>L. bouillonii</i>), and <i>L. confervoides</i>. Over the years, compounding evidence from in vitro and in vivo studies in support of the significant pharmaceutical potential of ‘<i>Lyngbya</i>’-derived natural products has made the <i>Lyngbya</i> morphotype a significant target for biomedical research and novel drug leads development. This comprehensive review covers compounds with reported anti-infective activities through 2022 from the <i>Lyngbya</i> morphotype, including new genera arising from recent phylogenetic re-classification. So far, 72 anti-infective secondary metabolites have been isolated from various <i>Dapis</i>, <i>Lyngbya</i>, <i>Moorea</i>, and <i>Okeania</i> species. These compounds showed significant antibacterial, antiparasitic, antifungal, antiviral and molluscicidal effects. Herein, a comprehensive literature review covering the natural source, chemical structure, and biological/pharmacological properties will be presented. |
| first_indexed | 2024-03-09T16:09:48Z |
| format | Article |
| id | doaj.art-325d6493d18648a292c57c5dcc854c65 |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-03-09T16:09:48Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-325d6493d18648a292c57c5dcc854c652023-11-24T16:19:52ZengMDPI AGMarine Drugs1660-33972022-12-01201276810.3390/md20120768Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022Diaa T. A. Youssef0Shatha J. Mufti1Abeer A. Badiab2Lamiaa A. Shaala3Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi ArabiaDepartment of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi ArabiaDepartment of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi ArabiaSuez Canal University Hospital, Suez Canal University, Ismailia 41522, EgyptCyanobacteria ascribed to the genus <i>Lyngbya</i> (Family Oscillatoriaceae) represent a potential therapeutic gold mine of chemically and biologically diverse natural products that exhibit a wide array of biological properties. Phylogenetic analyses have established the <i>Lyngbya</i> ‘morpho-type’ as a highly polyphyletic group and have resulted in taxonomic revision and description of an additional six new cyanobacterial genera in the same family to date. Among the most prolific marine cyanobacterial producers of biologically active compounds are the species <i>Moorena producens</i> (previously <i>L. majuscula,</i> then <i>Moorea producens</i>)<i>, M. bouillonii</i> (previously <i>L. bouillonii</i>), and <i>L. confervoides</i>. Over the years, compounding evidence from in vitro and in vivo studies in support of the significant pharmaceutical potential of ‘<i>Lyngbya</i>’-derived natural products has made the <i>Lyngbya</i> morphotype a significant target for biomedical research and novel drug leads development. This comprehensive review covers compounds with reported anti-infective activities through 2022 from the <i>Lyngbya</i> morphotype, including new genera arising from recent phylogenetic re-classification. So far, 72 anti-infective secondary metabolites have been isolated from various <i>Dapis</i>, <i>Lyngbya</i>, <i>Moorea</i>, and <i>Okeania</i> species. These compounds showed significant antibacterial, antiparasitic, antifungal, antiviral and molluscicidal effects. Herein, a comprehensive literature review covering the natural source, chemical structure, and biological/pharmacological properties will be presented.https://www.mdpi.com/1660-3397/20/12/768marine cyanobacteria<i>Lyngbya</i> morphotypesecondary metabolitesantibacterialantifungalantiparasitic |
| spellingShingle | Diaa T. A. Youssef Shatha J. Mufti Abeer A. Badiab Lamiaa A. Shaala Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 Marine Drugs marine cyanobacteria <i>Lyngbya</i> morphotype secondary metabolites antibacterial antifungal antiparasitic |
| title | Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 |
| title_full | Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 |
| title_fullStr | Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 |
| title_full_unstemmed | Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 |
| title_short | Anti-Infective Secondary Metabolites of the Marine Cyanobacterium <i>Lyngbya</i> Morphotype between 1979 and 2022 |
| title_sort | anti infective secondary metabolites of the marine cyanobacterium i lyngbya i morphotype between 1979 and 2022 |
| topic | marine cyanobacteria <i>Lyngbya</i> morphotype secondary metabolites antibacterial antifungal antiparasitic |
| url | https://www.mdpi.com/1660-3397/20/12/768 |
| work_keys_str_mv | AT diaatayoussef antiinfectivesecondarymetabolitesofthemarinecyanobacteriumilyngbyaimorphotypebetween1979and2022 AT shathajmufti antiinfectivesecondarymetabolitesofthemarinecyanobacteriumilyngbyaimorphotypebetween1979and2022 AT abeerabadiab antiinfectivesecondarymetabolitesofthemarinecyanobacteriumilyngbyaimorphotypebetween1979and2022 AT lamiaaashaala antiinfectivesecondarymetabolitesofthemarinecyanobacteriumilyngbyaimorphotypebetween1979and2022 |